Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue
Key Highlights
- ➤Preliminary Q3 revenue expected at $10.1 million-$10.4 million
- ➤Q3 revenue expected up approximately 11%-14% quarter over quarter
- ➤Q3 revenue expected up approximately 15%-18% year over year
- ➤Complete Q3 financial results remain subject to closing and accounting review
* Preliminary Q3 2026 revenue expected to range from $10.1 million to $10.4 million * Expected quarter-over-quarter growth of approximately 11% to 14% compared with Q2 2026 * Expected year-over-year growth of approximately 15% to 18% compared with Q3 2025 PARSIPPANY, NJ, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCID: IDXG) today announced that it expects preliminary, unaudited revenue for the third quarter ended September 30, 2026 to range from $10.1 million to $10.4 million.
The expected revenue range represents an increase of approximately 11% to 14% compared with revenue of $9.1 million for the second quarter of 2026 and an increase of approximately 15% to 18% compared with revenue of $8.8 million for the third quarter of 2025.
Get started
Create a free account to read the full story.